Zobrazeno 81 - 90
of 3,936
for search: '"35"'
Author/Creator:
Jasmine S. Sukumar, Sagar Sardesai, Andy Ni, Nicole Williams, Bhuvaneswari Ramaswamy, Robert Wesolowski, Mathew A. Cherian, Daniel Stover, Margaret Gatti-Mays, Ashley C. Pariser, Preeti K. Sudheendra, Mridula A. George, maryam lustberg
Published in:
Cancer Research. 83:P1-02
Background: Approximately 10% of breast cancers (BC) are hormone receptor positive (HR+) and HER2 positive (HER2+). Despite treatment advances in the modern era of HER2 targeted therapies for early-stage disease, there remains a risk for late relapse
Akademický článek
This result is not displayed to guests.
Login for full access.
Login for full access.
Author/Creator:
Joseph Geradts, Aisha Kousar, Jan Wong, Nasreen Vohra, Mahvish Muzaffar, Anas Mohamed
Published in:
Cancer Research. 82:P4-06
Background: The Oncotype DX Recurrence Score (RS) predicts recurrence and chemotherapy benefit in early stage estrogen receptor positive breast cancer patients. Cost and unavailability are two major disadvantages of the assay. Multiple models have be
Akademický článek
This result is not displayed to guests.
Login for full access.
Login for full access.
Author/Creator:
Martins F; School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.; Clinics of Medical Oncology, Cantonal Hospital of Fribourg (HFR), Fribourg, Switzerland., Rosspopoff O; School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland., Carlevaro-Fita J; School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland., Forey R; School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland., Offner S; School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland., Planet E; School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland., Pulver C; School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland., Pak H; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.; Agora Cancer Research Centre, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland., Huber F; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.; Agora Cancer Research Centre, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland., Michaux J; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.; Agora Cancer Research Centre, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland., Bassani-Sternberg M; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.; Agora Cancer Research Centre, Lausanne, Switzerland.; Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland., Turelli P; School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland., Trono D; School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Published in:
Cancer research [Cancer Res] 2024 Mar 15; Vol. 84 (6), pp. 808-826.
Author/Creator:
Huang F; Informatics Institute, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.; Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama., Xu P; Informatics Institute, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.; Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama., Yue Z; Informatics Institute, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.; Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama., Song Y; Informatics Institute, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.; Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama., Hu K; Informatics Institute, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.; Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama., Zhao X; Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas., Gao M; Informatics Institute, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.; Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama., Chong Z; Informatics Institute, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.; Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.; HudsonAlpha Institute for Biotechnology, Huntsville, Alabama.
Published in:
Cancer research [Cancer Res] 2024 Mar 04; Vol. 84 (5), pp. 757-770.
Author/Creator:
Young Kwang Chae, Megan Othus, Sandip P. Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic, Sajeve S. Thomas, William R. Robinson, Liam Il-Young Chung, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock
Published in:
Cancer Research. 83:CT163-CT163
Background: Dual checkpoint inhibition with Anti-PD-1 and anti-CTLA4 checkpoint inhibitors have shown to be efficacious in many malignancies, but its potential role in various rare solid cancers is yet to be established. Small cell ovarian carcinoma,
Author/Creator:
Mor Moskovitz, Isamu Okamoto, Peng Chen, Jilpa Patel, Sabeen Mekan, M. Catherine Pietanza, Yalin Zhu, Renata Eiras, Marcello Tiseo
Published in:
Cancer Research. 83:CT067-CT067
Background: Sacituzumab govitecan is an antibody-drug conjugate comprising an anti-trophoblast cell-surface antigen 2 (Trop-2) antibody coupled to a potent payload, SN-38, via a proprietary, hydrolysable linker. In heavily pretreated patients with me
Author/Creator:
Seongyeol Park, Suk Kyun Hong, Joonoh Lim, YoungRok Choi, Boram Yi, Jaemo Koo, June-Young Koh, Ryul Kim, Nam-Joon Yi, Jeong Seok Lee, Kyung-Suk Suh, Kwang-Woong Lee, Young Seok Ju
Published in:
Cancer Research. 83:2056-2056
Liver cancer is a leading cause of death worldwide where somatic mutation plays a key role in tumorigenesis. As such, many recent researches have been conducted using DNA sequencing methods to study somatic mutations in liver cancer, such as whole-ex
Author/Creator:
Mark Reid Groseclose, Jeremy Barry, Tinamarie Skedzielewski, Gerald McDermott, Chakravarthi Balabhadrapatruni, Bill Benson, Yongle Pang, David K. Lim, Hoang Tran, Mike Ringenberg, Keyur Gada, Amine Aziez, Elaine Paul, Hasan Alsaid
Published in:
Cancer Research. 83:3582-3582
Purpose: There remains an unmet need to provide effective treatment therapy for patients with primary and metastatic brain tumors; lack of drug penetration across the blood brain barrier (BBB) is a key factor. Synthetic lethality remains an attractiv